Genzyme and Anika Patent Dispute Continues

Cambridge, MA-based biotech Genzyme, now a unit of Sanofi-Aventis (NYSE:SNY), has amended its patent infringement lawsuit against its competitor Anika Therapeutics (NASDAQ:ANIK) related to Anika’s osteoarthritis treatment, Monovisc. Genzyme also filed a new complaint in U.S. District Court in Boston that includes a newly issued patent, according to Anika. Genzyme, the world’s largest maker of rare disease drugs, makes a product for knee joint pain from osteoarthritis called Synvisc-One that competes with Anika’s Monovisc. Both products are single injections of hyaluronic acid-based treatments. Bedford, MA-based Anika said in a statement yesterday that it plans to “vigorously defend the lawsuits and the Monovisc franchise.”

Trending on Xconomy